Nature Communications (Mar 2023)
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
- Teresa Lai Fong Ho,
- May Yin Lee,
- Hui Chin Goh,
- Germaine Yi Ning Ng,
- Jane Jia Hui Lee,
- Srinivasaraghavan Kannan,
- Yan Ting Lim,
- Tianyun Zhao,
- Edwin Kok Hao Lim,
- Cheryl Zi Jin Phua,
- Yi Fei Lee,
- Rebecca Yi Xuan Lim,
- Perry Jun Hao Ng,
- Ju Yuan,
- Dedrick Kok Hong Chan,
- Bettina Lieske,
- Choon Seng Chong,
- Kuok Chung Lee,
- Jeffrey Lum,
- Wai Kit Cheong,
- Khay Guan Yeoh,
- Ker Kan Tan,
- Radoslaw M. Sobota,
- Chandra S. Verma,
- David P. Lane,
- Wai Leong Tam,
- Ashok R. Venkitaraman
Affiliations
- Teresa Lai Fong Ho
- Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR)
- May Yin Lee
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Hui Chin Goh
- Cancer Science Institute of Singapore, National University of Singapore
- Germaine Yi Ning Ng
- Singapore Institute of Technology
- Jane Jia Hui Lee
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Srinivasaraghavan Kannan
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR)
- Yan Ting Lim
- Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Tianyun Zhao
- Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Edwin Kok Hao Lim
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Cheryl Zi Jin Phua
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Yi Fei Lee
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Rebecca Yi Xuan Lim
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Perry Jun Hao Ng
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Ju Yuan
- Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR)
- Dedrick Kok Hong Chan
- Nuffield Department of Surgical Sciences, University of Oxford
- Bettina Lieske
- Division of Colorectal Surgery, University Surgical Cluster, National University Health System
- Choon Seng Chong
- Division of Colorectal Surgery, University Surgical Cluster, National University Health System
- Kuok Chung Lee
- Division of Colorectal Surgery, University Surgical Cluster, National University Health System
- Jeffrey Lum
- Department of Pathology, National University Health System
- Wai Kit Cheong
- Division of Colorectal Surgery, University Surgical Cluster, National University Health System
- Khay Guan Yeoh
- University Surgical Cluster, National University Health System
- Ker Kan Tan
- Division of Colorectal Surgery, University Surgical Cluster, National University Health System
- Radoslaw M. Sobota
- Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Chandra S. Verma
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR)
- David P. Lane
- Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR)
- Wai Leong Tam
- Cancer Science Institute of Singapore, National University of Singapore
- Ashok R. Venkitaraman
- Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR)
- DOI
- https://doi.org/10.1038/s41467-023-37223-3
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
Here the authors identify distinct mechanisms by which domain-specific p53 mutations activate cancer cell growth via the epidermal growth factor receptor (EGFR). These mechanisms affect sensitivity to EGFR inhibitors, opening avenues for targeted therapy.
